Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases


Charles Perou and colleagues report on somatic mutations in primary tumors and metastases from two patients with basal-like breast cancer.


Published in the journal: . PLoS Med 13(12): e32767. doi:10.1371/journal.pmed.1002174
Category: Research Article
doi: 10.1371/journal.pmed.1002174

Summary

Charles Perou and colleagues report on somatic mutations in primary tumors and metastases from two patients with basal-like breast cancer.

Introduction

Breast cancer patients who die from their disease typically succumb to metastatic disease rather than to the primary tumor. Metastasis is a complex process likely involving many potentially distinct mechanistic steps. Biologically similar tumors vary in their ability to seed distant metastatic sites. Indeed, different molecular intrinsic subtypes of breast cancer as determined by the PAM50 subtype classifier vary markedly in their preferred sites for metastasis [13]. The luminal subtypes often metastasize to the bone, HER2-enriched tumors to the lung and liver, and basal-like and claudin-low tumors to the brain, lung, and liver [1,2]. The metastatic process is often described as a slow and continuous process of tumor evolution and acquisition of traits such as increased genomic instability, motility, and the epithelial-to-mesenchymal transition. Recent work in renal, prostate, ovarian, and lung cancer has identified significant amounts of intratumor variability in the primary tumor, as well as identifying new driver mutations that arose in metastases [48]. In several breast cancer analyses of targeted gene panels, there was considerable concordance of mutations observed between primary tumors and matched metastases [912]. This finding, combined with our increasing understanding that a particular intrinsic subtype predicts the future site(s) of metastasis, suggests that in breast cancer at least some of the metastatic potential already exists within the primary tumor [13,10]. To examine this further, we studied the genomic relationship between the primary tumors and multiple matched metastases of two patients with triple-negative breast cancer (TNBC), with both cases also of the basal-like breast cancer intrinsic subtype.

A common means of studying intratumor heterogeneity is to sample multiple parts of the same tumor and then perform genetic or genomic assays on these different regions. A more extreme approach to intratumor heterogeneity is to study a primary tumor and its associated metastases to determine the extent to which the metastatic tumor genome was derived from the primary tumor cells as opposed to being an independent tumor [57,13,14]. Whether metastases can develop from the primary tumor or require continued evolution and gain of additional mutations in order to metastasize remains unknown in basal-like breast cancers, and addressing this issue may have important implications for therapy. In order to study the genomic evolution of basal-like breast cancer, we performed DNA whole genome and mRNA sequencing on two patients with matched primary tumors and multiple distant metastases.

Methods

Patient Consent and Tissue Processing

Tumor tissue was obtained from metastatic breast cancer patients who consented to a rapid autopsy at the University of North Carolina prior to death. Patient consent for the autopsy was obtained in accordance with the UNC Office for Human Research Ethics (OHRE) and criteria established by the US Department of HHS, but this consent procedure was not IRB regulated. There was no prospective analysis plan for this study. For Patient A7, a diagnostic skin punch biopsy of the primary tumor was collected under protocol LCCC 9819 (NCT01000883) as a fresh-frozen sample. For Patient A1’s primary, all metastatic tissues, and normal tissues from both patients, collection was within 6 h of death for all metastatic sites identified prior to death and at time of autopsy. Tissues were frozen in liquid nitrogen, and RNA and DNA were isolated from each tissue using Qiagen RNAeasy and DNAeasy kits, respectively, according to manufacturer protocol (Qiagen, Valencia, California) (S1 Table).

RNA-Seq

RNA was isolated with RNeasy Mini Kit (Qiagen), and sequencing libraries were prepared with Illumina TruSeq RNA Sample Prep Kit (CAT #RS-122-2001) with the polyA select protocol, except for the A7-Brain, which was first prepared using the Epicentre’s Ribo-Zero rRNA Removal kit (Cat #RZH11042) [15]. RNA-seq was mapped with MapSplice [16] and quantified with RSEM [17]. Upper-quantile normalized counts, log2 transformed, were combined with the Cancer Genome Atlas (TCGA) breast RNA-seq data [18]. Samples were median centered and clustered using the human breast cancer intrinsic gene set list [19], in Cluster 3.0 [20] and visualized with Java TreeView v. 1.1.6r4 [21].

Illumina Library Construction and Whole Genome Sequencing

A previously described procedure was followed for library construction and sequencing [22]. Briefly, DNA was sheared (Covaris), end repaired (Lucigen), polyadenylated (Lucigen), and ligated to adapters (Illumina) for paired-end data generation. DNA sequencing was performed on the Illumina Genome Analyzer II and generated between 114 and 260 Gbp of sequence data for each tissue studied and haploid coverage ranging from 29.24 to 72.17 (S2 Table).

Mutation Detection Pipeline

Reads were aligned to human reference build 36 (ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/ARCHIVE/BUILD.36.3/special_requests/assembly_variants/; BWA 0.5.5, http://sourceforge.net/projects/bio-bwa/), merged into a single binary alignment map (BAM) file, with duplicate reads removed using Picard 1.07 (http://broadinstitute.github.io/picard/) by the established pipeline, as previously reported [23]. To determine somatic variants, we utilized samtools [24] followed by SomaticSniper using a somatic score ≥40 and mapping quality ≥40 [25,26]. Additional screening against dbSNP was used to remove probable germline variants [27,28]. Indels were identified with Pindel [29] and GATK [30]. All variants were further annotated as previously described [22,27] using VarScan2 [31] (parameters: --min-coverage = 30, --;min-var-freq = 0.08, --normal-purity = 1, --p-value = 0.10, --somatic-p-value = 0.001, --validation = 1) to classify mutations as reference, germline, somatic, or resulting from loss of heterozygosity (LOH). A Bayesian classifier was applied to retain the somatic variants with a binomial log-likelihood of at least 3 (parameters: --llr-cutoff = 3, --tumor-purity = 0.95). False positives, as determined by strand specificity, consistent positions near the ends of reads, and poorly mapped qualities were removed.

Mutations were assigned to four tiers: (1) coding, (2) conserved or regulatory, (3) unique noncoding, and (4) repetitive noncoding regions.

Structural Variant Detection

Structural variants (SVs) were called with BreakDancer [32] and filtered using TIGRA_SV [33]. Somatic copy number alterations were detected using CopyCat v1.6.9 (https://github.com/chrisamiller/copycat), with 10,000 bp windows and default parameters.

Experimental Validation of Mutations

SNP arrays

Genotypes from Illumina Human OmniExpress BeadChip SNP arrays were used to compare and confirm the heterozygous SNPs detected in the analyzed WGS data.

Small (1–2 bp) indels

Putative indels of 1–2 bp were converted to BED format and provided as target intervals for the GATK IndelRealigner [30,34]. The primary, metastases, and matched normal breast tissue for each patient were then realigned to these BED files independently. To validate the original predictions, we developed a matching algorithm that attempts to match Varscan validation calls with the original indel predictions, as described [23]. All validated somatic indels were then manually reviewed using Integrative Genomics Viewer (IGV) [35].

Medium (3–100 bp) indels

Indels of 3–100 bp were assembled using TIGRA [33] and validated as previously described [23]. Variants that passed the strict validation were manually reviewed.

Solid phase capture

Custom sequence capture validation was performed with Roche NimbleGen arrays for 97.3% of the Tier 1–3 somatic alterations and 68.6% of the SVs. Whole genome amplified DNA was prepared for Illumina sequencing according to the manufacturer’s protocol (Illumina, San Diego, California). DNA was fragmented with the Covaris S2 DNA Sonicator (Covaris, Woburn, Massachusetts), adapter-ligated, SPRI-bead cleaned, and PCR amplified. One μg of the 300–500 bp fragment library was hybridized to the NimbleGen HD2 probe set according to the manufacturer’s protocol (Nimblegen, Madison, Wisconsin). Following hybridization, the library was PCR amplified for 16 cycles and quantified with the KAPA SYBR FAST qPCR Kit (KAPA Biosystems, Woburn, Massachusetts) and diluted such that 180,000 clusters were sequenced per lane of the Illumina GAIIx.

Reads were mapped to the NCBI Build 36 reference WUGSC Variant, which is a subset of the NCBI36 sequences from Ensembl Release 46 (full assembly at ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/ARCHIVE/BUILD.36.3/special_requests/assembly_variants/).

The validation sequence was aligned with BWA v0.5.9, and duplicate reads were marked using Picard (v1.29). Updated versions of BWA and Picard were used for increased alignment speed and variant detection efficiency. The RefCov package was used to evaluate the coverage of target sequences (http://gmt.genome.wustl.edu/packages/refcov/).

Validation of SVs

Capture validation reads and mates were mapped to both the assembled SV contigs and the reference with CrossMatch (version 1.080721). The threshold for an acceptable alignment is ≤1 mismatch at either end, ≤1% substitutions, 1% indels, and a CrossMatch score ≥ 50. An SV-supporting read is required to span the breakpoint on the SV contig, align to 10 bases flanking on each side of the breakpoint, and have no alignment to the reference above the minimum alignment criteria. The somatic status of each SV was determined using Fisher’s exact test between the matched tumor and normal sample. All validated calls were manually reviewed.

RNA Validation of Mutations

UNCeqR [36] was run on validation mode for all samples. In validation mode, the algorithm accepts as input a set of predetermined mutations, such as a list of mutations generated from WGS/WES, and then looks within the RNA-seq data for expression evidence of the variants. Tier 1 mutations were input into UNCeqR along with the RNA-seq BAM files aligned with MapSplice [16]. UNCeqR then calculated the number of reads of the reference and variant alleles at each position interrogated. Mutations with less than 5 reads were considered as 0. RNA variant allele fraction (VAF) was calculated as variant allele reads/total reads.

Clonality Analyses

The clonal structure of each tumor was inferred with SciClone (version 1.0.7) [37], with parameters minDepth = 75, copyNumberMargins = 0.25, and maximumClusters = 20. Single nucleotide variants (SNVs) in copy number altered regions or with evidence of complete or partial LOH were reviewed and excluded. Phylogeny was inferred using the clonevol R package (https://github.com/hdng/clonevol) with default parameters.

Results

Case Histories

Patient A1 was a 65-y-old white woman who presented with stage IV TNBC and synchronous metastases to the bone of the vertebral column (spinal), lung, adrenal gland, liver, and lymph nodes. She was treated with radiation therapy to the breast, whole brain, and C3/T2 of the spine, had one cycle of palliative paclitaxel without response, and died of disease 2-mo postdiagnosis. Patient A7 was a 60-y-old African-American woman diagnosed with a 5-cm stage IIIA TNBC. A pretreatment primary tumor biopsy was collected as a part of an existing tissue collection protocol (LCCC 9819, NCT01000883), and she subsequently received neoadjuvant doxorubicin plus cyclophosphamide followed by paclitaxel. She underwent mastectomy with T2N2 residual disease, followed by adjuvant radiation therapy to the chest wall (SCV fossa and axillary nodes). Patient A7 remained without evidence of disease recurrence for 17 mo before presenting with metastases to the brain, kidney, liver, lung, and ribs. She received single-agent capecitabine for 4 mo, with an initial minimal response and then progression both systemically and in the central nervous system (CNS), followed by a single cycle of carboplatin that was discontinued because of poor tolerability and evidence of rapid progression. Patient A7 died of disease 8 mo after her metastatic progression. For both patients, fresh frozen tissue was collected at autopsy from primary tumor, distant metastases, and adjacent normal (nonmalignant breast) tissue, except for the primary tumor specimen that was obtained before neoadjuvant treatment was initiated in patient A7 (Fig 1).

Clinical history and distribution of metastases from patients A1 and A7, who both had clinically triple-negative and basal-like breast cancer.
Fig. 1. Clinical history and distribution of metastases from patients A1 and A7, who both had clinically triple-negative and basal-like breast cancer.

Whole Genome Sequencing Coverage and Mutation

For the matched normal tissues, primary tumor (pretreatment biopsy for A7), and distant metastases from patients A1 and A7, we performed DNA whole genome paired-end sequencing. For A7, we derived 138.38, 118.76, 260.93, 128.69, 204.34, 201.66, and 156.82 Gbp of sequencing data from normal tissue, primary tumor, liver, lung, rib, kidney, and brain metastases, respectively, with corresponding haploid coverages ranging from 33.17X to 70.19X (S2 Table). For A1, we generated 265.53, 134.07, 115.85, 210.45, 114.31, and 131.03 Gbp of data from normal tissue, primary tumor, liver, lung, adrenal, and spinal cord metastases, respectively, with haploid coverage ranging from 30X to 72.16X (S2 Table).

Candidate somatic changes were predicted using multiple algorithms. Confirmatory testing of heterozygous mutations with genotype arrays confirmed biallelic detection of 80.47% to 89.63% in all samples (S2 Table). Candidate mutations were further validated with capture probes corresponding to all putative somatic SNVs and small insertions/deletions (indels) that overlap with coding exons, splice sites, and RNA genes (Tier 1), a number of high-confidence SNVs and indels in noncoding conserved or regulatory regions (Tier 2), and nonrepetitive regions of the human genome (Tier 3). In addition, we included predicted somatic SVs for validation. We obtained 40X haploid reference coverage for 87.48% to 94.02% of the targeted sites (S3 Table). For A1, 73 Tier 1 point mutations, 1 Tier 1 indel, and 53 somatic SVs were confirmed across the primary tumor and metastases (S4S6 Tables). For A7, there were 150 Tier 1 point mutations, 47 indels, and 40 SVs confirmed in the primary tumor and five metastatic samples (S7S9 Tables).

Genomic Relatedness of Primary Tumors and Metastases

Common gene expression patterns throughout metastasis

In order to study the degree of relatedness between a primary tumor and its metastases, we performed mRNA-seq gene expression analyses followed by hierarchical clustering analysis using a breast cancer “intrinsic” gene list [19] including data from the 11 specimens studied here and 1,100 breast tumors from the TCGA Project [18]. Regardless of physical or temporal distance between the primary and its metastases, all tumors from these two patients clustered tightly together by patient (Fig 2). By gene expression analysis using the PAM50 intrinsic breast cancer subtype predictor [19], the primary tumors and metastases all maintained a basal-like subtype phenotype and clustered with the basal-like samples from TCGA (Fig 2B); previous research has demonstrated a high correlation among primaries and matched metastases by microarray gene expression [1,38]. In patient A1, in whom the primary tumor and distant metastases were found synchronously and who had limited exposure to chemotherapy and radiation prior to death, the gene expression hierarchical cluster node correlation for the primary and the four metastases was 0.77 (Fig 2C). In patient A7, who received neoadjuvant chemotherapy and radiation and had a 17-mo interval separating the discovery of the primary tumor and distant metastases, the node correlation for the six samples was 0.79 (Fig 2C). This demonstrates that subtype was maintained throughout metastasis in these two patients and that, as we and others have shown [1,38], distant metastases are typically much more similar to their original primary than they are to other primary tumors or metastases from other patients.

Molecular relatedness of matched primary and metastases.
Fig. 2. Molecular relatedness of matched primary and metastases.
(A) Hierarchical clustering of patient A1 and A7’s tumors with 1,100 TCGA Primary samples and 98 normal breast samples analyzed using a breast cancer intrinsic gene list. The color bars under the dendrogram indicate (i) where A1 (red) and A7 (blue) specimens are clustered and (ii) the PAM50 subtype of each sample (basal-like, red; HER2-enriched, pink; luminal A, dark blue; luminal B, light blue; and normal-like, green). (B) The position of A1 (red) and the position of A7 (blue) within the basal-like cluster are highlighted. (C) The relationship of the primary and metastases for each patient based upon gene expression patterns.

Functional mutations are maintained and enriched during metastasis

We next studied DNA-based data from each primary tumor and its multiple distant metastases. In patient A1, 54 genes were mutated with a VAF greater than 0.5% in the primary tumor (13 nonsilent mutations were in the Catalogue of Somatic Mutations in Cancer [COSMIC] [39]) (S4 Table). Almost every Tier 1 mutation present in the A1 primary tumor was identified in one or more of the metastases (52/54), and in many cases the VAF was enriched in the metastasis (median: 5-fold enrichment, average: 8.8-fold, range: 1- to 38-fold; S4 Table, S1 Fig). Eleven mutated genes were shared among the primary and all matched metastases: TARBP1, FCRL1, XIRP1, TRMT1, PANX3, MYSM1, PHLDB3, TBC1D25, LOC284288, MDS2, and TP53. The adrenal metastasis and spinal metastasis contained the most unique SNVs, with seven and nine, respectively. The liver metastasis and lung metastasis did not have any private mutations at a VAF > 1%, although the lung metastasis did share two mutations with the adrenal metastasis that were not observed in the primary.

In patient A7, 75 Tier 1 genes were mutated with a VAF ≥ 0.4% in the primary tumor (14 of these nonsilent mutations were in COSMIC) (S7 Table, S1 Fig). The VAF in all of the metastases had a median enrichment of 1.4-fold, closer to the primary tumor than in patient A1. All of the mutations identified in the primary tumor were detected in at least one metastasis, and 65 mutations, including mutations in RUNX1T1, ADGRB2, KMT2C, RP1, TP53, and AKT3, were shared across the primary and all matched metastases. There were 75 mutations identified in one or more of the metastases that were not observed in the primary tumor (8 of these nonsilent mutations also were in COSMIC). The majority of these metastasis-specific mutations (54/75) were present in two or more metastases. Of the 21 mutations private to a single metastasis, the liver and kidney metastases had the most, with 7 and 8 private mutations, respectively. The rib metastasis contained no unique mutations.

TP53 as a common driver of metastasis

TP53 alterations are frequently observed in basal-like breast cancers [40]. TP53 was the only shared somatic mutated gene between the two patients and was present in every tumor specimen sequenced. Close examination of patient A1 data identified an 11 bp deletion in TP53 that was common to all samples (S2 Fig). In patient A7, the TP53 missense mutation H168R had a greater than 68% VAF in all tumors except the brain metastasis (31%). While this exact mutation was not observed in the TCGA breast cohort, a missense mutation was identified at the same position in one case (H168P) [41,42], supporting the likelihood that alteration of TP53 is a founding event critical for the development of basal-like breast cancer [43] and subsequent metastasis.

Mutations established early tend to be expressed and enriched in metastasis

We examined the mRNA expression data for evidence of expression of the somatic point mutations in primary tumors and metastases. Interestingly, mutations shared between the primary and metastatic tumors were more likely to be expressed (Fig 3, black dots) and were expressed at higher levels than mutations unique to metastasis (Fig 3, blue dots). In patient A1, 21/52 (40%) of the mutations established in the primary were expressed in the metastases (Fig 3A, black dots). In patient A7, 47/75 (63%) of the mutations established in the primary were expressed both in the primary and in the metastases (Fig 3B, black dots).

Gene expression of variant alleles.
Fig. 3. Gene expression of variant alleles.
Variant allele fractions (VAFs) of each point mutation were determined from mRNA-sequencing data and compared to those from combined whole genome sequencing (WGS) and validation sequencing data. Gene variants shared in the primary and metastases (shared mutations, black), metastases but not primaries (metastases specific, blue), or only in one metastasis (private, red) in patients A1 (A) and A7 (B) are shown.

Fewer mutations were detected only in the metastases, and those mutated transcripts had lower RNA expression than mutations shared with the primary (Fig 3, blue dots). In patient A1, 2 of the 3 mutations shared among more than one metastasis but not in the primary tumor were expressed (Fig 3A, blue dots), while only 4 of the 18 private mutations (detected only in individual metastases) were expressed (S4 Table, Fig 3A, red dots). In patient A7, 23/54 (43%) of the mutations that were shared across the metastases but not with the primary tumor were expressed, and 8/21 (38%) of the private mutations were expressed (S7 Table, Fig 3B).

Interestingly, many of the expressed metastasis-specific mutations occur in genes that are involved in DNA damage responses, RNA processing, and degradation of the extracellular matrix (ECM). In patient A1, metastasis-specific mutations included FANCF and SMC6 (DNA double-stranded break repair), DDX6 (promotes mRNA degradation), and HYAL3 (degrades hyaluronan in the ECM) [44]. In patient A7, AQR, DOCK6, and HLTF were shared across metastases and expressed. Metastasis-specific mutations in patient A7 included CASC3 (the core of the exon junction complex), TIMP3 (degrades ECM), and LAMA5 (part of the ECM) [44]. These could represent convergent evolutionary paths to the resistance of DNA damaging agents and promotion of cell mobility and survival.

Structural variations tend to be established early in metastasis

To further explore the development of larger genomic alterations during metastasis, Circos plots were generated to illustrate the combined Tier 1 somatic mutations, DNA copy number alterations, and SVs for each sequenced tumor (patient A1: S4S6 Tables, S3 Fig; patient A7: S7S9 Tables, S4 Fig). These illustrate that, overall, SVs were mostly established in the primary tumor and maintained through the different metastatic processes.

In patient A1, all 8 of the SVs in the primary tumor were shared with the metastases (S3 Fig), including one that was specifically shared with the adrenal and liver metastases (S6 Table). The metastases had few additional interchromosomal SVs, and these were shared, except in the spinal metastasis. Interestingly, the spinal metastasis evolved to have many more rearrangements between chromosomes 2 and either 3, 8, 12, or 16.

In patient A7, the brain and kidney metastases shared most interchromosomal SVs with the primary (S4 Fig, S9 Table). The rib and liver metastases had three private SV alterations each (of a total of six and eight alterations, respectively), while the lung metastasis showed many more private interchromosomal SVs than the other metastatic samples.

FBXW7-INPP4B fusion in patient A7

To confirm SVs, we created a modified genome that represented the possible new alignments in RNA space. Realigning A7 data to this map demonstrated expression of an FBXW7-RNF150 fusion gene observed in all A7 samples, indicating early fusion of this gene in the development of this patient’s breast cancer (S5 Fig). Interestingly, deletion of the last ten exons of FBXW7 was previously reported as a founding event in a basal-like breast cancer [45]. The 5′ end of the fusion in patient A7 began at exon 3 or 4 of FBXW7, which likely inactivated FBXW7. The 3′ end of the fusion occurred just before RNF150, resulting in deletion of INPP4B. There was decreased RNA expression of INPP4B in this patient, further supporting the deletion of INPP4B by the FBXW7-RNF150 fusion gene event. INPP4B has important implications in breast cancer that include DNA repair defects [46], increased genomic instability [47], and inhibition of the PI3K pathway [48].

Multiclonal Evolution of Metastasis in Two Patients with TNBC

To understand the Darwinian evolution occurring in the primary tumor and throughout metastasis [49], we established the subclonal relationships and phylogenetic trees for patient A1 (Fig 4, S6S8 Figs, S10 Table) and patient A7 (Fig 5, S9 and S10 Figs, S11 Table).

Clonality analysis of each tumor from patient A1.
Fig. 4. Clonality analysis of each tumor from patient A1.
VAFs among the primary and matched metastases in patient A1 (A) and a representative evolutionary tree (B) colored by subclone based on the clonality plots in panel A, with the width of the branch indicating the approximate percentage of that clone within the tumor. Clone 1 is established in the primary tumor and seeded all distant metastases. Clones 2 and 4 from the primary tumor seeded the liver and the adrenal gland, with clone 7 concurrently seeding the liver from the primary tumor. Clones 3 and 5 from the primary tumor seeded the lung, with clone 3 also seeding the spine. Private clones include clone 6, specific to the adrenal metastasis; clone 8, specific to the primary tumor; and clone 9, specific to the spinal metastasis.

Clonality analysis of each tumor from patient A7.
Fig. 5. Clonality analysis of each tumor from patient A7.
Clonality shared among the primary tumor and matched metastases in patient A7 (A) and the representative evolutionary tree (B) colored by subclone identity based on the clonality plots in panel A, with the width representative of the percentage of the clone within that tumor. Clone 1 was established in the primary tumor and maintained through metastatic spread in every tumor. Clone 2 was present in the liver, kidney, and rib and at a low frequency in the lung, while clones 3 and 5 were shared by the liver and kidney metastases. Clone 6 was present in the rib and a low frequency in the lung metastases. Brain and lung metastases shared clone 4. Four metastases had a private clone not shared with any other tumor: clone 7 specific to the lung, clone 8 specific to the kidney, clone 9 specific to the liver, and clone 10 private to the brain.

Subclonality analysis using Sciclone of the A1 patient samples demonstrates that the primary tumor predominantly contained clones 1, 3, 5, and 8, with very low allele fractions of minor clones 2, 4, and 7 (S6 Fig, Fig 4A). Clone 1, established in the primary tumor, seeded all other metastases. Of the other major clones in the primary, clones 3 and 5 seeded the lung metastasis, while clone 3 additionally seeded the spinal metastasis. This metastasis then continued to evolve, developing private clone 9 (Fig 4A, S6 Fig). These clones (3 and 5) were mutually exclusive with minor clone 2, which was found in the primary tumor, lung, liver, and adrenal metastases (S7 Fig). Two of the minor clones in the primary tumor (clones 2 and 4) became the dominant clones in the liver and adrenal metastases, with additional private subclonal evolution in the adrenal metastasis (clone 6). Interestingly, clone 7 was established in the primary tumor and also metastasized to the liver, but not to the adrenal, metastasis (Fig 4B). Using ClonEvol, there were two potential models for clone 7 development that we were not able to fully resolve; either it evolved (1) from clone 4 (S7A Fig) or (2) independently from clone 2 (S7B and S8 Figs). This result demonstrates that the multiclonal metastatic potential residing in the primary tumor is maintained through metastasis.

Importantly, patient A1 presented at stage IV and only received two doses of radiation and one cycle of single-agent taxane before death. Thus, her primary-to-metastatic disease likely is representative of the natural course of basal-like breast cancer rather than representing selection from the evolutionary pressure imposed by therapy.

In patient A7, the subclonal structure was determined by SciClone (S9 Fig, S11 Table), and a single model of evolution was suggested by ClonEvol (S10 Fig). The primary tumor consisted of one main clone (Fig 5A), seeding all other sites of metastasis at the highest VAF observed. The main clone then diverged to two lineages, giving rise to clone 2 predominantly in the liver, kidney, and rib and clone 4 predominantly in the lung and brain (Fig 5B). Clone 4 is present in the lung and brain metastases at an almost equivalent VAF to the founding clone 1. Clones 2 and 6 in the rib are also present at an almost equivalent VAF to clone 1; clones 2 and 6 are seen at a low VAF in the lung. These clonal data paint a complex picture with two possible explanations: either the split of clone 1 into clones 2 and 6 and clone 4 occurred prior to metastatic spread (Solution A, Fig 5B) or these clones cross seeded from the rib metastasis to the lung metastasis (Solution B, Fig 5B). Clone 2 further evolved to clones 3 and 5 in the liver and kidney metastases. We favor the first hypothesis, namely that clone 2 in the rib, liver, and kidney metastases is at a VAF equivalent to the founding clone, indicating that the evolution of this clone occurred before metastatic seeding. All metastases aside from the rib metastasis also contained private subclones.

Discussion

Whole genome sequencing and mRNA sequencing of two TNBC/basal-like breast cancer patients with primary tumors and multiple matched metastases demonstrated significant genetic similarity between the primary breast cancers and their matched metastases. Patient A1 demonstrated significant intratumoral heterogeneity established in the primary tumor and multiclonal seeding of metastasis. Interestingly, patient A7 possibly contained a more homogenous primary breast cancer that then led to diverse, heterogeneous metastases. Even though there is continued evolution, the acquisition of mutations private to a single metastasis likely had limited impact on the metastatic potential, as these mutations were rarely expressed or were expressed at low levels. In contrast to earlier findings in renal cell carcinoma of monoclonal metastasis seeding [4], basal-like breast cancer metastases can be the result of multiclonal seeding of cells established in the primary. The results presented here are inconsistent with a single cell of a primary breast cancer seeding a distant metastasis [50]. Herein, we describe an example of multiple subclones that resided within a primary tumor followed by multiclonal seeding of all distant metastases as well as a common disruption of TP53.

In both patients, relatively few mutations occurred once the tumor cells left the primary site, and of those that did alter protein coding sequences, the mutations were not highly expressed at the RNA level in general. The high correlation of gene expression among primaries and matched metastases illustrates that subtype is typically maintained throughout metastasis [1], and that specific intrinsic subtypes have an inherent tendency to metastasize to specific organs [1,3]. Taken together, these results suggest that the metastatic potential was present within the primary tumor of these two basal-like breast cancer patients. Here, we uncover a genetic explanation for the close correlation of gene expression in metastases and matched primaries—namely that, in the two cases examined, the samples from a given individual were much more genetically similar than they were dissimilar, both on the DNA and RNA levels.

While the majority of genetic alterations present in metastases were shared with the matched primary cancer in these two patients examined, we also identified a significant amount of intratumoral heterogeneity, evident because multiple subclones were detected within each metastasis. Patient A1 demonstrates that more than one subclone from the primary seeded each metastasis, and the intratumoral heterogeneity in the primary tumor setting was mostly reflected in each metastasis. In patient A7, the lung metastasis exhibited diverse intratumoral heterogeneity, with two small subclones (2 and 6) found at high frequency in three of the other metastases. There are two possible explanations for the complex clonal patterns seen in patient A7: either the two dominant clones (clones 2 and 4) were established in the primary and were not sampled in the piece of the primary tumor that was actually sequenced, or clones 2 and 6 in the rib cross seeded into the lung metastasis. While one metastasis seeding another metastasis has been previously demonstrated in prostate cancer [7], we also recognize that the A7 primary breast cancer likely had spatial heterogeneity that was not fully captured by our sequencing [51]. In fact, the A7 primary breast cancer piece sequenced was a skin punch biopsy taken from a 5 cm primary breast cancer, rather than a tumor resection. Hence, samples from multiple portions of this tumor were not sequenced. Of the two possibilities, the most parsimonious explanation for the observations relevant to patient A7 is that multiclonal seeding of the metastases did occur and that our limited sample did not permit detection of clones 2 and 6. Hence, only subsequent deep sequencing of additional portions of the A7 tumor would resolve the issue of monoclonal versus multiclonal seeding from the primary. Unfortunately, no additional specimens exist for this patient. Regardless of this, in patient A7 multiple multiclonal seeding events were discovered, such as the rib metastasis seeding the kidney and liver.

The genetic heterogeneity in both of the primary tumors and the resulting metastases may explain why many metastatic TNBC patients fail to have a durable treatment response and instead progress within a few years [52]. In particular, heterogeneity provides for a wealth of individual genotypes, thus yielding a genetic diversity from which chemotherapy resistance may arise. Treatment has been shown to select for therapy-resistant clones in primary breast cancer [5355], and therapy can select for subclones in the metastatic setting.

While our studies provided evidence of multiclonal seeding of metastasis in these two patients, both with basal-like breast cancer, our results may or may not apply to a larger cohort of patients with basal-like breast cancers, to other subtypes of breast cancers, or to other cancer types. Even within the poor-prognosis basal-like subtype, patients often receive many more lines of therapy and have more favorable responses to their therapies for a longer duration than the two patients presented here. Furthermore, patients with luminal and HER2-enriched breast cancer have comparatively more opportunities to benefit from targeted therapies such as tamoxifen, aromatase inhibitors, and/or HER2 agonists such as trastuzumab, lapatinib, or pertuzumab. Since neither patient A1 nor A7 was treated with targeted therapies, there were different selective pressures in the metastatic setting compared to current standard of care for ER+ and HER2+ patients.

The basal-like subtype is a highly aggressive cancer that often metastasizes to the lung and brain within 5 y of diagnosis. This is in contrast to luminal A breast cancers, which are typically more indolent, are less likely to progress to stage IV, and typically metastasize first to the bone [56]. The difference in these patterns of relapse and the timing with which they occur suggest fundamental differences in disease progression between the subtypes [57] within the context of drastically different treatment strategies. Continued analyses of larger datasets representing each of the subtypes and patients with varying clinical histories will be necessary to identify consistently altered genes to define early versus late drivers, metastasis-site specific alterations, and differences among the mechanisms of metastasis across various subtypes of breast cancer.

Supporting Information

Attachment 1

Attachment 2

Attachment 3

Attachment 4

Attachment 5

Attachment 6

Attachment 7

Attachment 8

Attachment 9

Attachment 10

Attachment 11

Attachment 12

Attachment 13

Attachment 14

Attachment 15

Attachment 16

Attachment 17

Attachment 18

Attachment 19

Attachment 20

Attachment 21

Attachment 22


Zdroje

1. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012;132: 523–35. doi: 10.1007/s10549-011-1619-7 21671017

2. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res BCR. 2011;13: R87. doi: 10.1186/bcr2944 21914172

3. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68: 3108–3114. doi: 10.1158/0008-5472.CAN-07-5644 18451135

4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366: 883–892. doi: 10.1056/NEJMoa1113205 22397650

5. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346: 256–259. doi: 10.1126/science.1256930 25301631

6. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346: 251–256. doi: 10.1126/science.1253462 25301630

7. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520: 353–357. doi: 10.1038/nature14347 25830880

8. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLOS Med. 2015;12: e1001789. doi: 10.1371/journal.pmed.1001789 25710373

9. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5: 1164–1177. doi: 10.1158/2159-8290.CD-15-0369 26410082

10. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 2014;13: 1382–1389. doi: 10.1158/1535-7163.MCT-13-0482 24608573

11. Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232: 23–31. doi: 10.1002/path.4288 24122263

12. Moelans CB, van der Groep P, Hoefnagel LDC, van de Vijver MJ, Wesseling P, Wesseling J, et al. Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Lett. 2014;344: 138–146. doi: 10.1016/j.canlet.2013.10.025 24184827

13. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015;373: 1926–1936. doi: 10.1056/NEJMoa1502583 26559571

14. McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hirst G, Vuong P, et al. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat Med. 2015;21: 1514–1520. doi: 10.1038/nm.3979 26523969

15. Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. BMC Genomics. 2014;15: 419. doi: 10.1186/1471-2164-15-419 24888378

16. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010;38: e178. doi: 10.1093/nar/gkq622 20802226

17. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12: 323. doi: 10.1186/1471-2105-12-323 21816040

18. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015;163: 506–519. doi: 10.1016/j.cell.2015.09.033 26451490

19. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27: 1160–1167. doi: 10.1200/JCO.2008.18.1370 19204204

20. de Hoon MJL, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004;20: 1453–1454. doi: 10.1093/bioinformatics/bth078 14871861

21. Saldanha AJ. Java Treeview—extensible visualization of microarray data. Bioinformatics. 2004;20: 3246–3248. doi: 10.1093/bioinformatics/bth349 15180930

22. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361: 1058–1066. doi: 10.1056/NEJMoa0903840 19657110

23. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150: 1121–1134. doi: 10.1016/j.cell.2012.08.024 22980976

24. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinforma Oxf Engl. 2009;25: 2078–2079. doi: 10.1093/bioinformatics/btp352 19505943

25. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinforma Oxf Engl. 2012;28: 311–317. doi: 10.1093/bioinformatics/btr665 22155872

26. Larson DE, Abbott TE, Wilson RK. Using SomaticSniper to Detect Somatic Single Nucleotide Variants. Curr Protoc Bioinforma Ed Board Andreas Baxevanis Al. 2014;15: 15.5.1–15.5.8. doi: 10.1002/0471250953.bi1505s45 25431635

27. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456: 66–72. doi: 10.1038/nature07485 18987736

28. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29: 308–311. 11125122

29. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinforma Oxf Engl. 2009;25: 2865–2871. doi: 10.1093/bioinformatics/btp394 19561018

30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20: 1297–1303. doi: 10.1101/gr.107524.110 20644199

31. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22: 568–576. doi: 10.1101/gr.129684.111 22300766

32. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods. 2009;6: 677–681. doi: 10.1038/nmeth.1363 19668202

33. Chen K, Chen L, Fan X, Wallis J, Ding L, Weinstock G. TIGRA: a targeted iterative graph routing assembler for breakpoint assembly. Genome Res. 2014;24: 310–317. doi: 10.1101/gr.162883.113 24307552

34. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43: 491–498. doi: 10.1038/ng.806 21478889

35. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14: 178–192. doi: 10.1093/bib/bbs017 22517427

36. Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, et al. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 2014;42: e107. doi: 10.1093/nar/gku489 24970867

37. Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014;10: e1003665. doi: 10.1371/journal.pcbi.1003665 25102416

38. Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget. 2016; doi: 10.18632/oncotarget.8349 27028851

39. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43: D805–D811. doi: 10.1093/nar/gku1075 25355519

40. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490: 61–70. doi: 10.1038/nature11412 23000897

41. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2: 401–404. doi: 10.1158/2159-8290.CD-12-0095 22588877

42. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6: pl1. doi: 10.1126/scisignal.2004088 23550210

43. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486: 395–399. doi: 10.1038/nature10933 22495314

44. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating information about genes, proteins and diseases. Trends Genet TIG. 1997;13: 163. 9097728

45. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464: 999–1005. doi: 10.1038/nature08989 20393555

46. Ip LRH, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, et al. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. Oncotarget. 2015;6: 10548–10562. doi: 10.18632/oncotarget.3307 25868852

47. Weigman VJ, Chao H-H, Shabalin AA, He X, Parker JS, Nordgard SH, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133: 865–880. doi: 10.1007/s10549-011-1846-y 22048815

48. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009;16: 115–125. doi: 10.1016/j.ccr.2009.06.006 19647222

49. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A. 2008;105: 13081–13086. doi: 10.1073/pnas.0801523105 18723673

50. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472: 90–94. doi: 10.1038/nature09807 21399628

51. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21: 751–759. doi: 10.1038/nm.3886 26099045

52. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncol Williston Park. 2008;22: 1233–1239. 18980022

53. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Rep. 2013;4. doi: 10.1016/j.celrep.2013.08.022 24055055

54. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2015;518: 240–244. doi: 10.1038/nature13948 25409150

55. Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun. 2016;7: 12498. doi: 10.1038/ncomms12498 27502118

56. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades. Cancer Epidemiol Biomarkers Prev. 2012;21: 1848–1855. doi: 10.1158/1055-9965.EPI-12-0474 22989461

57. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486: 353–360. doi: 10.1038/nature11143 22722193

Štítky
Interní lékařství

Článek vyšel v časopise

PLOS Medicine


2016 Číslo 12

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
nový kurz
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: Prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Familiární transthyretinová periferní polyneuropatie
Autoři: MUDr. Radim Mazanec, Ph.D.

Diabetes mellitus a kardiovaskulární riziko, možnosti jeho ovlivnění
Autoři:

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se